Recent Research Analysts’ Ratings Changes for BioTelemetry (BEAT)

BioTelemetry (NASDAQ: BEAT) recently received a number of ratings updates from brokerages and research firms:

  • 8/2/2019 – BioTelemetry was downgraded by analysts at Raymond James from an “outperform” rating to a “market perform” rating.
  • 8/2/2019 – BioTelemetry was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “BioTelemetry, Inc. provides ambulatory outpatient management solutions for monitoring clinical information regarding an individual’s health. It is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. BioTelemetry, Inc., formerly known as CardioNet, Inc., is headquartered in Conshohocken, Pennsylvania. “
  • 8/1/2019 – BioTelemetry was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $53.00 price target on the stock. According to Zacks, “BioTelemetry, Inc. provides ambulatory outpatient management solutions for monitoring clinical information regarding an individual’s health. It is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. BioTelemetry, Inc., formerly known as CardioNet, Inc., is headquartered in Conshohocken, Pennsylvania. “
  • 7/31/2019 – BioTelemetry had its price target lowered by analysts at Raymond James from $62.00 to $54.00. They now have an “outperform” rating on the stock.
  • 7/31/2019 – BioTelemetry was given a new $90.00 price target on by analysts at Lake Street Capital. They now have a “buy” rating on the stock.
  • 7/31/2019 – BioTelemetry had its price target lowered by analysts at Sidoti from $95.00 to $87.00. They now have a “buy” rating on the stock.
  • 7/23/2019 – BioTelemetry was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 7/18/2019 – BioTelemetry was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 6/26/2019 – BioTelemetry was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 6/26/2019 – BioTelemetry was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “BioTelemetry, Inc. provides ambulatory outpatient management solutions for monitoring clinical information regarding an individual’s health. It is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. BioTelemetry, Inc., formerly known as CardioNet, Inc., is headquartered in Conshohocken, Pennsylvania. “
  • 6/10/2019 – BioTelemetry was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “BioTelemetry, Inc. provides ambulatory outpatient management solutions for monitoring clinical information regarding an individual’s health. It is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. BioTelemetry, Inc., formerly known as CardioNet, Inc., is headquartered in Conshohocken, Pennsylvania. “
  • 6/7/2019 – BioTelemetry was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Shares of BEAT traded up $0.94 during midday trading on Monday, reaching $42.97. 656,766 shares of the stock were exchanged, compared to its average volume of 552,237. BioTelemetry Inc has a twelve month low of $39.41 and a twelve month high of $80.92. The company has a current ratio of 2.19, a quick ratio of 1.84 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $1.42 billion, a P/E ratio of 22.15 and a beta of 1.32. The firm has a 50 day moving average of $47.71.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings results on Tuesday, July 30th. The medical research company reported $0.53 EPS for the quarter, beating the Zacks’ consensus estimate of $0.45 by $0.08. The business had revenue of $111.80 million during the quarter, compared to the consensus estimate of $111.11 million. BioTelemetry had a return on equity of 22.98% and a net margin of 11.06%. BioTelemetry’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.46 earnings per share. Research analysts expect that BioTelemetry Inc will post 1.96 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the stock. Stephens Investment Management Group LLC raised its stake in BioTelemetry by 42.4% during the second quarter. Stephens Investment Management Group LLC now owns 668,530 shares of the medical research company’s stock worth $32,190,000 after acquiring an additional 199,171 shares in the last quarter. Eagle Asset Management Inc. bought a new stake in shares of BioTelemetry during the first quarter worth about $31,052,000. Carillon Tower Advisers Inc. grew its holdings in shares of BioTelemetry by 284.2% during the first quarter. Carillon Tower Advisers Inc. now owns 478,632 shares of the medical research company’s stock worth $29,972,000 after purchasing an additional 354,043 shares during the last quarter. Rothschild & Co. Asset Management US Inc. grew its holdings in shares of BioTelemetry by 28.2% during the second quarter. Rothschild & Co. Asset Management US Inc. now owns 398,105 shares of the medical research company’s stock worth $19,169,000 after purchasing an additional 87,601 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of BioTelemetry by 11.8% during the fourth quarter. Geode Capital Management LLC now owns 376,618 shares of the medical research company’s stock worth $22,490,000 after purchasing an additional 39,722 shares during the last quarter. 92.04% of the stock is owned by institutional investors and hedge funds.

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

Featured Story: Why are gap-down stocks important?

Receive News & Ratings for BioTelemetry Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc and related companies with MarketBeat.com's FREE daily email newsletter.